Hypertensive left ventricular hypertrophy risk: Beyond adaptive cardiomyocytic hypertrophy

Journal of Hypertension

Volumn 29, Issue 1, 2011, Pages 17-26

  Frohlich, Edward D ^a   González, Arantxa ^b   Díez, Javier ^b,c  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b Centre of Applied Medical Research   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

arterial hypertension; hypertensive heart disease; left ventricular hypertrophy; myocardial hypertrophy; myocardial remodelling

Indexed keywords

AMLODIPINE; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; CANDESARTAN; DICHLOROACETIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; FUROSEMIDE; SPIRONOLACTONE; TORASEMIDE;

CARDIOVASCULAR RISK; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE; HEART MUSCLE CELL; HUMAN; HYPERTENSION; LOW DRUG DOSE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 78650826193     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328340d787     Document Type: Review

References (113)

1. Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 2008; 358:1370-1378.
2. McMullen JR, Jennings GI. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 2007; 34:255-262.
3. Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 2010. [Epub ahead of print]
4. De Simone G, Gottdiener JS, Chinali M, Maurer MS. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur Heart J 2008; 29:741-747.
5. Krauser DG, Devereux RB. Ventricular hypertrophy and hypertension: prognostic elements and implications for management. Herz 2006; 31:305-316.
6. Lip GY, Felmeden DC, Li-Saw-Hee FL, Beevers DG. Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'? Eur Heart J 2000; 21:1653-1665.
7. Katz AM. Maladaptive growth in the failing heart: the cardiomyopathy of overload. Cardiovasc Drug Ther 2002; 16:245-249.
8. Diamond JA, Phillips RA. Hypertensive heart disease. Hypertens Res 2005; 28:191-202.
9. D́ez J, Frohlich ED. A translational approach to hypertensive heart disease. Hypertension, 2010, 55, 1-8
10. Raman SV. The hypertensive heart: an integrated understanding informed by imaging. J Am Coll Cardiol 2010; 55:91-96.
11. Alpert NR, Mulieri LA. Increased myothermal economy of isometric force generation in compensated cardiac hypertrophy induced by pulmonary artery constriction in the rabbit. A characterization of heat liberation in normal and hypertrophied right ventricular papillary muscles. Circ Res 1982; 50:491-500.
12. Swynghedauw B, Delcayre C, Samuel J-L, Mebazaa A, Cohen-Solal A. Molecular mechanisms in evolutionary cardiology failure. Ann N Y Acad Sci 2010; 1188:58-67.
13. Samuel JL, Swynghedauw B. Is cardiac hypertrophy a required compensatory mechanism in pressure-overloaded heart? J Hypertens 2008; 26:857-858.
14. Buckberg GD, Coghlan HC, Torrent-Guasp F. The structure and function of the helical heart and its buttress wrapping. V. Anatomic and physiological considerations in the healthy and failing heart. Semin Thorac Cardiovasc Surg 2001; 13:358-385.
15. Akki A, Smith K, Seymour AM. Compensated cardiac hypertrophy is characterized by a decline in palmitate oxidation. Mol Cell Biochem 2008; 311:215-224.
16. De las Fuentes L, Herrero P, Peterson LR, Kelly DP, Gropler RJ, Dávila-Román VG, Myocardial fatty acid metabolism: independent predictor of left ventricular mass in hypertensive heart disease. Hypertension, 2003, 41, 83-87.
17. Van Bielsen M, van Nieuwenhoven FA, van Der Vusse GJ. Metabolic remodelling in the failing heart: beneficial or detrimental. Cardiovasc Res 2009; 81:420-428.
18. Beer M, Seyfarth T, Sandstede J, Landschütz W, Lipke C, Köstler H, et al. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol 2002; 40:1267-1274.
19. Lamb HJ, Beyerbacht HP, van Der Laarse A, Stoel BC, Doornbos J, van Der Wall EE, de Roos A. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 1999; 99:2261-2267.
20. Wende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta 2010; 1801:311-319.
21. Lehman JJ, Kelly DP. Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail Rev 2002; 7:175-185.
22. Barry SP, Davidson SM, Townsend PA. Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol 2008; 40:2023-2039.
23. Rajabi M, Kassiotis C, Razeghi P, Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev 2007; 12:331-343.
24. Dorn GW II, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005; 115:527-537.
25. Baker KM, Chernin MI, Schreiber T, Sanghi S, Haiderzaidi S, Booz GW, et al. Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regul Pept 2004; 120:5-13.
26. Aoki H, Izumo S. Signal transduction of cardiac myocyte hypertrophy. In: Sperelakis N, Kurachi Y, Terzic A, Cohen MV, editors. Heart physiology, pathology. 4th ed. San Diego: Academic Press; 2001. pp. 1065-1086.
27. Akazawa H, Komuro I. Roles of cardiac transcription factors in cardiac hypertrophy. Circ Res 2003; 92:1079-1088.
28. Olson EN, Backs J, McKinsey TA. Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation. Novartis Found Symp 2006; 274:3-12.
29. Latronico MV, Catalucci D, Condorelli G. MicroRNA and cardiac pathologies. Physiol Genomics 2008; 34:239-242.
30. Frohlich ED. Target organ involvement in hypertension: a realistic promise of prevention and reversal. Med Clin North Am 2004; 88:209-221.
31. Díez J, Gonzalez A, López B, Querejeta R. Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med 2005; 2:209-216.
32. Kong SW, Bodyak N, Yue P, Liu Z, Brown J, Izumo S, Kang PM. Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats. Physiol Genomics 2005; 21:34-42.
33. Strøm CC, Aplin M, Ploug T, Christoffersen TE, Langfort J, Viese M, et al. Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. FEBS J 2005; 272:2684-2695.
34. Feihl F, Liaudet L, Waeber B. The macrocirculation and microcirculation of hypertension. Curr Hypertens Res 2009; 11:182-189.
35. Lapu-Bula R, Ofili E. From hypertension to heart failure: role of nitric oxide-mediated endothelial dysfunction and emerging insights from myocardial contrast echocardiography. Am J Cardiol 2007; 99:7D-14D.
36. London GM, Guerin AP. Influence of arterial pulse and reflected waves on blood pressure and cardiac function. Am Heart J 1999; 138:220-224.
37. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15:264-272.
38. Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 2002; 27:92-98.
39. McLenachan JM, Dargie JH. Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relation to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens 1990; 3:735-740.
40. Frohlich ED. Fibrosis and ischemia: the real risks in hypertensive heart disease. Am J Hypertens 2001; 14:194S-199S.
41. Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006; 118:10- L 14.
42. Young MJ. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr Opin Nephrol Hypertens 2008; 17:174-180.
43. González A, López B, Ravassa S, Querejeta R, Larman M, D́ez J, Fortuño MA. Stimulation of apoptosis in essential hypertension: potential role of angiotensin II. Hypertension 2002; 39:75-80.
44. Yamamoto S, Sawada K, Shimomura H, Kawamura K, James TN. On the nature of cell death during remodeling of hypertrophied human myocardium. J Mol Cell Cardiol 2000; 32:161-175.
45. Ravassa S, González A, López B, Beaumont J, Querejeta R, Larman M, Díez J. Upregulation of myocardial annexin A5 in hypertensive heart disease: association with systolic dysfunction. Eur Heart J 2007; 28:2785-2791.
46. Narula J, Arbustini E, Chandrashekhar Y, Schwaiger M. Apoptosis and the systolic dysfunction in congestive heart failure. Story of apoptosis interruptus and zombie myocytes. Cardiol Clin 2001; 19:113-126.
47. Wang ZW, Rothermel BA, Hill JA. Autophagy in hypertensive heart disease. J Biol Chem 2010; 285:8509-8514.
48. Bleeker GB, Bax JJ, Steendijk P, Schalij MJ, van Der Wall EE. Left ventricular dyssynchrony in patients with heart failure: pathophysiology, diagnosis and treatment. Nat Clin Pract Cardiovasc Med 2006; 3:213-219.
49. Spragg DD, Kass DA. Pathobiology of left ventricular dyssynchrony and resynchronization. Progr Cardiovasc Dis 2006; 49:26-41.
50. De Marchi SF, Allemann Y, Seiler C. Relaxation in hypertrophic cardiomyopathy and hypertensive heart disease: relations between hypertrophy and diastolic dysfunction. Heart 2000; 83:678-684.
51. Tan H, Zheng G, Li L, Wang Z, Gong H, Zhang Y, et al. Impaired left ventricular synchronicity in hypertensive patients with ventricular hypertrophy. J Hypertens 2008; 26:553-559.
52. De Simone G, Pasanisi F, Contaldo F, Linking of nonhemodynamic factors to hemodynamic determinants of left ventricular hypertrophy. Hypertension, 2001, 38, 13-18.
53. D́ez J, Towards a new paradigm about hypertensive heart disease. Med Clin North Am, 2009, 93, 637-645.
54. Kuwahara K, Kinoshita H, Kuwahara Y, Nakagawa Y, Usami S, Minami T, et al. MRTF-A is a common mediator of mechanical stress- and neurohumoral stimulation-induced cardiac hypertrophic signaling leading to activation of BNP gene expression. Mol Cell Biol 2010; 30:4134-4148.
55. Small EM, Thatcher JE, Sutherland LB, Kinoshita H, Gerard RD, Richardson JA, et al. Myocardin-related transcription factor-A controls myofibroblast activation and fibrosis in response to myocardial infarction. Circ Res 2010; 107:294-304.
56. Singh VP, Le B, Bhat VB, Baker KM, Kumar R. High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol 2007; 293:H939-H948.
57. Singh VP, Baker KM, Kumar R. Activation of the intracellular renin- angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. Am J Physiol Heart Circ Physiol 2008; 294:H1675-H1684.
58. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes 2008; 57:3297-3306.
59. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, et al. Myocardial cell death in human diabetes. Circ Res 2000; 87:1123-1132.
60. Deschepper CF, Boutin-Ganache I, Zahabi A, Jiang Z. In search of cardiovascular candidate genes. Interactions between phenotypes and genotypes. Hypertension 2002; 39:332-336.
61. Kuznetsova T, Staessen J, Thijs L, Kunath C, Olszanecka A, Ruabikov A, et al. Left ventricular mass in relation to genetic variation in angiotensin II receptors, renin system genes, and sodium excretion. Circulation 2004; 110:2644-2650.
62. Piro M, Dell Bona R, Abbate A, Biasucci LM, Crea F. Sex-related differences in myocardial remodeling. J Am Coll Cardiol 2010; 55:1057-1065.
63. Varagic J, Frohlich ED, D́ez J, Susic D, Ahn J, González A, López B. Myocardial fibrosis, impaired coronary hemodynamics, and biventricular dysfunction in salt-loaded SHR. Am J Physiol Heart Circ Physiol 2006; 290:H1503-H1509.
64. Matavelli LC, Zhou X, Varagic J, Susic D, Frohlich ED. Salt-loading produces severe renal hemodynamic dysfunction independent of arterial pressure in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2007; 292:H814-H819.
65. Varagic J, Frohlich ED, Susic D, Ahn J, Matavelli L, López B, D́ez J. AT1 receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure. Am J Physiol Heart Circ Physiol 2008; 294:H853-H858.
66. Akki A, Seymour AM. Western diet impairs metabolic remodeling and contractile efficiency in cardiac hypertrophy. Cardiovasc Res 2009; 81:610-617.
67. Majane OH, Vengethasamy L, du Toit EF, Makaula S, Woodiwiss AJ, Norton GR. Dietary-induced obesity hastens the progression from concentric cardiac hypertrophy to pump dysfunction in spontaneously hypertensive rats. Hypertension 2009; 54:1376-1383.
68. De Simone G, Verdecchia P, Pede S, Maggioni AP. Prognosis of inappropriate left ventricular mass in hypertension the MAVI Study. Hypertension 2002; 40:470-476.
69. De Simone G, Kitzman DW, Palmieri V, Liu JE, Oberman A, Hopkins PN, et al. Association of inappropriate left ventricular mass with systolic and diastolic dysfunction. Am J Hypertens 2004; 17:828-833.
70. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, et al. The heart in hypertension. N Engl J Med 1992; 327:998-1008.
71. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009; 54:1084-1091.
72. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, Porcellati C. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003; 16:895-899.
73. Verdecchia P, Gentile G, Angeli F, Mazzotta G, Mancia G, Reboldi G. Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. J Hypertens 2010; 28:1356-1365.
74. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292:2350-2356.
75. Agabiti-Rosei E, Mancia G, O'Rourke MF, Roman MJ, Safar ME, Smulyan H, et al. Central blood pressure measurements and antihypertensive therapy. A consensus document. Hypertension 2007; 50:154-160.
76. López B, Querejeta R, Varo N, González A, Larman M, Martínez Ubago JL, D́ez J. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104:286-291.
77. Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, et al. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination with Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease. Circulation 2009; 120:1380-1389.
78. Zanchetti A. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? J Hypertens 2009; 27:1509-1520.
79. López B, Querejeta R, González A, Beaumont J, Larman M, D́ez J. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009; 53:236-242.
80. Trackman PC. Diverse biological functions of extracellular collagen processing enzymes. J Cell Biochem 2005; 96:927-937.
81. Reudelhuber TL, Bernstein KE, Delafontaine P. Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look. Hypertension 2007; 49:1196-1201.
82. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25:951-958.
83. 1 receptor. Am J Physiol Cell Physiol, 2006, 291, C995-C1001.
84. Ernsberger P, Koletsky RJ. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr Opin Pharmacol 2007; 7:140-145.
85. 1-receptor blockade in acute myocardial ischemia. J Pharmacol Exp Ther 2007; 323:210-216.
86. Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119:530-537.
87. Jansen P, Danser AHJ, Imholz BP, van den Meiracker AH. Aldosterone-receptor antagonism in hypertension. J Hypertens 2009; 27:680-691.
88. Nishikawa N, Yamamoto K, Sakata Y, Mano T, Yoshida J, Umekawa S, et al. Long-term effect of spironolactone on cardiac structure as assessed by analysis of ultrasonic radio-frequency signals in patients with ventricular hypertrophy. Circ J 2005; 69:1394-1400.
89. Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res 2002; 25:837-842.
90. Taniguchi I, Kawai M, Date T, Yoshida S, Seki S, Taniguchi M, et al. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. Circ J 2006; 70:995-1000.
91. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108:1831-1838.
92. Mak GJ, Ledwidge MT, Watson CJ, Phelan DM, Dawkins IR, Murphy NF, et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009; 54:1674-1682.
93. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29:13-21.
94. Yamanaka S, Tatsumi T, Shiraishi J, Mano A, Keira N, Matoba S, et al. Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes. J Am Coll Cardiol 2003; 41:870-878.
95. González A, López B, Ravassa S, Beaumont J, Arias T, Hermida N, et al. Biochemical markers of myocardial remodelling in hypertensive heart diseases. Cardiovasc Res 2009; 81:509-518.
96. López B, González A, D́ez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 2010; 121:1645-1654.
97. Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation 2004; 109:1580-1589.
98. Oka S, Ago T, Kitazono T, Zablocki D, Sadoshima J. The role of redox modulation of class II histone deacetylases in mediating pathological cardiac hypertrophy. J Mol Med 2009; 87:785-791.
99. Van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007; 316:575-579.
100. 3 receptor regulates cardiac hypertrophy in response to select stimuli. Circ Res 2010; 107:659-666.
101. Toischer K, Rokita AG, Unsöld B, Zhu W, Kararigas G, Sossalla S, et al. Differential cardiac remodeling in preload versus afterload. Circulation 2010; 122:993-1003.
102. Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 2010; 122:717-728.
103. Kolwicz SC, MacDonnell SM, Renna BF, Reger PO, Seqqat R, Rafiq K, et al. Left ventricular remodeling with exercise in hypertension. Am J Physiol Heart Circ Physiol 2009; 297:H1361-H1368.
104. Garciarena CD, Pinilla OA, Nolly MB, Laguens RP, Escudero EM, Cingolani HE, et al. Endurance training in the spontaneously hypertensive rat: conversion of pathological into physiological cardiac hypertrophy. Hypertension 2009; 53:708-714.
105. McMullen JR, Amirahmadi F, Woodcock EA, Schinke-Braun M, Bouwman RD, Hewitt KA, et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 2007; 104:612-617.
106. Fazio S, Palmieri EA, Affuso F, Cittadini A, Castellano G, Russo T, et al. Effects of growth hormone on exercise capacity and cardiopulmonary performance in patients with chronic heart failure. J Clin Endocrinol Metab 2007; 92:4218-4223.
107. Heineke J, Auger-Messier M, Xu J, Oka T, Sargent MA, York A, et al. Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J Clin Invest 2007; 117:3198-3210.
108. Susic D, Francischetti A, Frohlich ED. Prolonged L-arginine on cardiovascular mass and myocardial hemodynamics and collagen in aged spontaneously hypertensive rats and normal rats. Hypertension 1999; 33:451-455.
109. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007; 49:241-248.
110. Ingwall JS. Energy metabolism in heart failure and remodeling. Cardiovasc Res 2009; 81:412-419.
111. Kato T, Niizuma S, Inuzuka Y, Kawashima T, Okuda J, Tamaki Y, et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 2010; 3:420-430.
112. Rohr S. Myofibroblasts in diseased hearts: new players in cardiac arrhythmias? Heart Rhythm 2009; 6:848-856.
113. Landmesser U, Wollert KC, Drexler H. Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc Res 2009; 81:519-527.